-
Options Brief: VIVUS, Inc. (VVUS)
Monday, March 28, 2011 - 12:11pm | 104Shares of VIVUS, Inc. (NASDAQ: VVUS) are lower on the session by 2.19%, trading at $6.25. Overall call volume is now running at 3.76x the daily average, wit 51% of all calls traded being purchases on the offer. 5,252 contracts have traded on the session so far. VIVUS, Inc. is a biopharmaceutical...
-
Morning Market Movers (NVGN, OBCI, RURL, ONSM)
Monday, March 28, 2011 - 9:48am | 135Novogen Limited (NASDAQ: NVGN) shares surged 75.47% to $1.86 at 9:45 am. NVGN shares have dipped 52.04% over the past 52 weeks, while the S&P 500 index has gained 12.62% in the same period. Ocean Bio-Chem Inc (NASDAQ: OBCI) shares advanced 44.19% to $3.10. OBCI reported a 92% y/y jump in its...
-
Repros Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Monday, March 28, 2011 - 9:34am | 204Repros Therapeutics (NASDAQ: RPRX) today announced financial results for the year and fourth quarter ended December 31, 2010. Financial Results Net loss for the three-month period ended December 31, 2010, was ($1.2) million or ($0.13) per share as compared to a net loss of ($1.3) million or ($0....
-
Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer
Monday, March 28, 2011 - 9:00am | 40PRINCETON, N.J. - March 28, 2011 (Investorideas.com Newswire) - Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
-
Pharma/Biotech Stock News: FDA Approves YERVOY (ipilimumab) for the Treatment of Patients with Newly Diagnosed or Previously-Treated Unresectable or Metastatic Melanoma, the Deadliest Form of Skin Cancer
Monday, March 28, 2011 - 9:00am | 40PRINCETON, N.J. - March 28, 2011 (Investorideas.com Newswire) - Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
-
Deutsche Bank Updates On BMY Yervoy Approval
Monday, March 28, 2011 - 8:02am | 115Deutsche Bank has released an update on Bristol-Myers Squibb (NYSE: BMY) following the FDA Approval of Yervoy. According to Deutsche Bank, "FDA approval for Yervoy was expected, including severe labeling for potential irAEs, REMS for HC professionals and a patient medication guide. However,...
-
Jefferies Has Buy On ViroPharma Inc. (VPHM)
Monday, March 28, 2011 - 7:37am | 191Jefferies & Co. has a Buy rating and a $24 price target on shares of ViroPharma Inc. (NASDAQ: VPHM). In a note to investors, Jefferies writes, "General Allergists Wary Of Steroids – Opportunity For Cinryze Marketing. Opinions among physicians for prophylactic therapies for HAE were split, and...
-
A Peek Into The Market Before The Trading Starts
Monday, March 28, 2011 - 7:34am | 390Pre-open movers US stock futures are slightly higher this morning, as investors are awaiting economic data. Futures on the Dow Jones Industrial Average gained 13 points to 12,183.00, while futures on the S&P 500 index rose 1.60 points to 1,311.60. Nasdaq 100 futures climbed 6 points to 2,323.00...
-
UPDATE: Goldman Sachs Raises PT on Bristol-Myers Squibb to $32 (BMY)
Monday, March 28, 2011 - 7:15am | 96Goldman Sachs is out with its report on Bristol-Myers Squibb (NYSE: BMY), raising its price target from $30 to $32. In a note to clients, Goldman Sachs writes, "We raise our 12-month price target to $32 (from $30) based on 15X our revised 2013E EPS of $2.07. BMY is becoming more biotech than...
-
Independent Data Monitoring Committee Recommends Continuation of Spectrum Pharmaceuticals' Pivotal Registrational Study of Belinostat
Monday, March 28, 2011 - 7:02am | 58Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that the independent Data Monitoring Committee, per protocol, has performed a safety and futility analysis and has recommended that the pivotal, registrational study for belinostat in relapsed or refractory Peripheral T-Cell Lymphoma, the “...
-
Dr. Reddy's Launches Levocetirizine Tablets in US
Monday, March 28, 2011 - 6:52am | 73Dr. Reddy's Laboratories (NYSE: RDY) has launched Levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal® tablets in the US market. The United States Food & Drug Administration (USFDA) approved Dr. Reddy's ANDA for Levocetirizine tablets on February 24, 2011. Levocetirizine...
-
US Stock Futures Up As Investors Await Economic Data, Crude Oil Drops To $104.92 a barrel
Monday, March 28, 2011 - 6:30am | 466US stock futures are slightly higher this morning, as investors are awaiting economic data. Futures on the Dow Jones Industrial Average gained 12 points to 12,182, while futures on the S&P 500 index rose 1.3 points to 1,311.30. Nasdaq 100 futures climbed 6.75 points to 2,323.75. US stocks...
-
AstraZeneca to Pay $1 Billion+ to Resolve U.S. Tax Dispute (AZN)
Monday, March 28, 2011 - 6:28am | 126AstraZeneca has agreed to pay more than $1 billion to settle an ongoing dispute over its U.S. tax liabilities, according to the Financial Times. The drugmaker said Monday that it would pay $1.1 billion to resolve disagreements over transfer pricing and other valuation issues in the period between...
-
Mad Money Lightning Round: Cramer Likes Alcoa, Health Care REIT (AA, SPPI, PANL, PFE, GILD, CELG, MRK, ABT, AGNC, NLY, HCN)
Monday, March 28, 2011 - 2:03am | 305On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Alcoa (AA) is “one of my absolute favorite stocks. This is an ultimate Japanese reconstruction story. This company is in fabulous shape." He said that Spectrum Pharmaceuticals (SPPI) is “an interesting speculation. It hasn't...
-
Watson Confirms OxyContin Patent Challenge
Friday, March 25, 2011 - 4:11pm | 92Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiaries, Andrx Labs, LLC and Watson Laboratories, Inc. -- Florida, filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxycodone Hydrochloride Extended-...